End of induction MRD assessment based early treatment intensification with novel agents in ETP-ALL- may be the way forward.

导出 LinkOut

翻译打印收藏纠错

作者： Pritish Chandra,Patra ^[1] ; Sujay,Rainchwar ^[1] ; Reema,Singh ^[1] ; Rohan,Halder ^[1] ; Pallavi,Mehta ^[1] ; Megha,Verma ^[1] ; Rayaz,Ahmed ^[1] ; Jyoti Shankar,Raichaudhuri ^[1] ; Dinesh,Bhurani ^[1] ; Narendra,Agrawal ^[1] ; Suman,Pramanik ^[2]

作者单位： Department of Hemato-Oncology and BMT, Rajiv Gandhi Cancer Institute and Research Centre, Delhi, India. ^[1] Clinical Hematology, Army Hospital, Delhi, India. ^[2]

DOI 10.5045/br.2023.2022241

PMID 37160382

发布时间 2023-07-03

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览1

Blood research

2023年58卷2期

112-115页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

End of induction MRD assessment based early treatment intensification with novel agents in ETP-ALL- may be the way forward.

Blood research

相似文献

Blood research

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

End of induction MRD assessment based early treatment intensification with novel agents in ETP-ALL- may be the way forward.

Blood research

相似文献

Blood research

相关期刊

检索历史清除